Cerulean Pharma Inc. (CERU) Appoints Vice President, Clinical Operations

Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting™, today announced the appointment of Tiffany Crowell as Vice President, Clinical Operations.

"Tiffany comes to Cerulean with deep experience and demonstrated leadership in clinical development and operations that will be crucial in supporting our clinical development of CRLX101 and CRLX301," said Paul Friedman, MD, Executive Chairman of Cerulean.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.